Azik Fatih M, Tezer Hasan, Ozkaya-Parlakay Aslinur, Aksu Tekin, Bayram Cengiz, Fettah Ali, Tavil Betül, Tunç Bahattin
*Pediatric Hematology Unit ‡Pediatric Infectious Disease Unit, Ankara Hematology Oncology Children's Training and Research Hospital †Gazi University Faculty of Medicine Pediatric Infectious Diseases Unit, Ankara, Turkey.
J Pediatr Hematol Oncol. 2015 Jan;37(1):e19-22. doi: 10.1097/MPH.0000000000000175.
Invasive fungal infections (IFIs) constitute a leading cause of morbidity and infection-related mortality among hematopoietic stem cell transplant (HSCT) recipients. With the use of secondary prophylaxis, a history of IFI is not an absolute contraindication to allo-HSCT. However, still, IFI recurrence remains a risk factor for transplant-related mortality. In this study, of the 105 children undergoing HSCT between April 2010 and February 2013, 10 patients who had IFI history before transplantation and had undergone allo-HSCT were evaluated retrospectively to investigate results of secondary prophylaxis. In conclusion, our study shows that amphotericin B and caspofungin was successful as secondary antifungal prophylaxis agents with no relapse of IFI. In addition, after engraftment, secondary prophylaxis was continued with voriconazole orally in 4 patients that yielded good results.
侵袭性真菌感染（IFI）是造血干细胞移植（HSCT）受者发病和感染相关死亡的主要原因。采用二级预防措施时，IFI病史并非异基因HSCT的绝对禁忌证。然而，IFI复发仍是移植相关死亡的危险因素。在本研究中，对2010年4月至2013年2月期间接受HSCT的105例儿童中，10例移植前有IFI病史且接受了异基因HSCT的患者进行回顾性评估，以调查二级预防的结果。总之，我们的研究表明，两性霉素B和卡泊芬净作为二级抗真菌预防药物是成功的，IFI无复发。此外，移植后，4例患者继续口服伏立康唑进行二级预防，效果良好。
